Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
about
Acute lymphoblastic leukaemiaTargeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureRecent advancements of bortezomib in acute lymphocytic leukemia treatmentRecent advances and novel treatment paradigms in acute lymphocytic leukemiaFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentThe role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.New Therapeutic Strategies in Acute Lymphocytic Leukemia.Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia.Treatment-refractory multi-lineage autoimmune cytopenia after unrelated cord blood transplantation: remission after combined bortezomib and vincristine treatment.Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemiaA Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology GroupChallenges of clinical trial design for targeted agents against pediatric leukemias.Novel agents for the treatment of childhood acute leukemia.Improving access to novel agents for childhood leukemia.Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United StatesPatterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia.Molecular profiling of childhood cancer: Biomarkers and novel therapiesAdvances in paediatric cancer treatmentBortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemiaA 50-year journey to cure childhood acute lymphoblastic leukemiaProteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapyHigher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments.Proteasome inhibitors in acute leukemia.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Novel targeted therapies in acute lymphoblastic leukemia.Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development.Novel approaches to pediatric leukemia treatment.Natural compounds for pediatric cancer treatment.Adolescent and young adult non-Hodgkin lymphoma.Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.The role of bortezomib in the treatment of acute lymphoblastic leukemia.
P2860
Q24602387-E9FF9CFC-5ADD-482D-8DC3-189B97EA03EFQ26746934-79EF05D3-5DC7-4864-B46D-49E61B97F102Q26829613-35B77C34-C836-4B8B-A0E8-BB1B43727B22Q28078076-78D28A7F-EAE0-4974-8D95-394BEAB93D36Q28533949-73E5CDB0-D04D-4A44-ABAD-E391E0D4903DQ30248842-AC34E7F9-AE57-4F20-8879-C740FEB90099Q30252776-B671E2C5-2D4D-4A16-91C2-38C0D3F9A6AAQ33414592-92A49B95-3015-4F28-B65F-157BEDF7F2B7Q33416169-55FB968F-B434-49B5-BE8F-B12AEC0E3BB3Q33694514-3AA39388-F45B-4044-BAAB-33EB8AADB4BEQ33711119-78AF6393-1D85-449F-B169-B172171059E9Q33742779-A01B40E1-EB0F-479E-AAF8-7E628F1195C5Q33828073-526B01B9-FA81-4AD2-BC07-8D46DFFAD131Q34585047-AE551EBD-0D2F-4588-A83F-429EDBB8B4CBQ34839887-143EDB92-C103-45B0-98B2-154A698AE902Q35192790-7E206D34-CBD7-4A05-BBB4-7B05EF6F6F7BQ35688742-FBB8E083-7F46-4FBD-9DD3-65F15639EAE5Q35957567-E5A7D846-CB48-40D0-A843-E4B83049C364Q36176588-16A7D0B1-3526-42EF-A10A-2EDB0EC18B4CQ36250783-922480BB-F9B6-479B-8D9B-4BC32E34A952Q36508630-EC3A6010-621B-4E4F-ACFF-FE6ADDBBEA92Q36545969-889F8A1E-1054-4130-B1FF-4F20D970257FQ36738818-EE3EA2EE-09B7-4709-975B-5D9725BB942BQ36955757-DA8094A8-9916-4F2F-A9AD-22D781FA9C15Q37166753-D4F2311C-AFC4-495E-9503-ADF3DB7B9028Q37233146-B6587E2C-C6E1-4314-8000-1C89B7F594EEQ37377911-2E69147B-8DE6-439C-B685-36D2BC3B287AQ37643136-7C99D63E-8EC2-4FF2-900C-8B3348FA98D9Q37723478-B74241C5-EB8D-4DE4-954B-FE0B1B89C21AQ38033592-C54CA2DE-487F-4196-B035-ED9F28378FF2Q38088003-11839EE5-C998-4BF5-8FFD-416689A51968Q38097334-47C831EB-07E2-4201-88F4-17E5D55F615CQ38120551-87B54E6F-749A-4C4A-B4C0-7D8E9C897687Q38164108-75FF551A-2B51-4ECE-BF3B-18E9897ABE2DQ38282458-CC294EF7-8DFE-4B90-9F34-AD2BB15DED04Q38500371-042F7535-2EB8-4538-950A-BEBDEE102AF0Q38663897-E244EB4B-9AD2-4DF6-AC4E-63F052D72F19Q38806478-B01AC26B-C99D-4BA0-9C1C-05282A6D4FD0Q38813978-FC8548B5-B090-464E-8530-263BD39708D9Q38833230-E878EFFF-85CC-4CAF-849D-5F5CA9D5728F
P2860
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.
@ast
Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.
@en
Bortezomib with chemotherapy i ...... Childhood Leukemia & Lymphoma
@nl
type
label
Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.
@ast
Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.
@en
Bortezomib with chemotherapy i ...... Childhood Leukemia & Lymphoma
@nl
prefLabel
Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.
@ast
Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.
@en
Bortezomib with chemotherapy i ...... Childhood Leukemia & Lymphoma
@nl
P2093
P1433
P1476
Bortezomib with chemotherapy i ...... kemia & Lymphoma (TACL) Study.
@en
P2093
Bruce C Bostrom
Elena Eckroth
Jeannette van der Giessen
Jemily Malvar
Richard Sposto
Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium
Yoav H Messinger
P304
P356
10.1182/BLOOD-2012-04-418640
P407
P577
2012-05-31T00:00:00Z